Immunotherapy Combination That Targets TIGIT Receptor Shows Promise in Non-Small Cell Lung Cancer: The ASCO Plenary Series
Read research from the December 2022 session of the ASCO Plenary Series, which explores combining immunotherapy for advanced non-small cell lung cancer with high PD-L1.